Moroni, Francesca
Dwyer, Benjamin J.
Graham, Catriona
Pass, Chloe
Bailey, Laura
Ritchie, Lisa
Mitchell, Donna
Glover, Alison
Laurie, Audrey
Doig, Stuart
Hargreaves, Emily
Fraser, Alasdair R. http://orcid.org/0000-0001-7822-650X
Turner, Marc L.
Campbell, John D. M.
McGowan, Neil W. A.
Barry, Jacqueline
Moore, Joanna K.
Hayes, Peter C.
Leeming, Diana J.
Nielsen, Mette J.
Musa, Kishwar
Fallowfield, Jonathan A. http://orcid.org/0000-0002-5741-1471
Forbes, Stuart J. http://orcid.org/0000-0003-3715-2561
Funding for this research was provided by:
RCUK | Medical Research Council (MR/M007588/1, MR/M007588/1, MR/M007588/1)
RCUK | MRC | Medical Research Foundation (MR/M007588/1)
Article History
Received: 12 May 2019
Accepted: 29 August 2019
First Online: 7 October 2019
Competing interests
: J.A.F. reports personal fees from Novartis, Ferring Pharmaceuticals, Galecto Biotech, Caldan Therapeutics, Gilde Healthcare, Arix Bioscience, Guidepoint and grants from GlaxoSmithKline, Novartis and Intercept Pharmaceuticals, outside the submitted work. S.J.F. has a grant from Syncona to develop macrophages as a therapy. D.J.L., K.M. and M.J.N. are full-time employees at Nordic Bioscience. D.J.L., M.K. and M.J.N. are among the original inventors and patent holders of C3M and PRO-C3. D.J.L. holds stock in Nordic Bioscience. P.C.H. is an advisor for AbbVie, BMS, Eisai Ltd, Falk, Ferring, Gilead, Gore, Janssen, Lundbeck, MSD, Norgine, Novartis, ONO Pharmaceuticals, Pfizer and Roche, outside the submitted work.